<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Defibrillation testing (DT) has been an integral part of defibrillator (implantable cardioverter defibrillator [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>]) implantation; however, there is little evidence that it improves outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>Surveys show a trend toward <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation without DT, which now exceeds 30% to 60% in some regions </plain></SENT>
<SENT sid="2" pm="."><plain>Because there is no evidence to support dramatic shift in practice, a randomized trial is urgently needed </plain></SENT>
<SENT sid="3" pm="."><plain>The SIMPLE trial will determine if <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation without any DT is noninferior to implantation with DT </plain></SENT>
<SENT sid="4" pm="."><plain>Patients will be eligible if they are receiving their first <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> using a Boston Scientific device (Boston Scientific, Natick, MA) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients will be randomized to DT or no DT at the time of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="6" pm="."><plain>In the DT arm, physicians will make <z:hpo ids='HP_0000001'>all</z:hpo> reasonable efforts to ensure 1 successful intraoperative defibrillation at 17 J or 2 at 21 J </plain></SENT>
<SENT sid="7" pm="."><plain>The first clinical shock in <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001649'>tachycardia</z:hpo> zones will be set to 31 J for <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>The primary outcome of SIMPLE will be the composite of ineffective appropriate shock or arrhythmic <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The safety outcome of SIMPLE will include a composite of potentially DT-related procedural complications within 30 days of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="10" pm="."><plain>Several secondary outcomes will be evaluated, including <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality and <z:hpo ids='HP_0001635'>heart failure</z:hpo> hospitalization </plain></SENT>
<SENT sid="11" pm="."><plain>Enrollment of 2,500 patients with 3.5-year mean follow-up will provide sufficient statistical power to demonstrate noninferiority </plain></SENT>
<SENT sid="12" pm="."><plain>The study is being performed at approximately 90 centers in Canada, Europe, Israel, and Asia Pacific with final results expected in 2013 </plain></SENT>
</text></document>